Advances in understanding the molecular basis of primitive neuroectodermal tumors of the central nervous system (CNS-PNET) biology are critical to improve patient outcome. Recently, new data on their molecular features have been reported, suggesting that supratentorial PNET (s-PNET) in adult patients may represent a specific tumor entity among CNS-PNETs. In this study, we analyzed the clinicopathologic and molecular features of 12 cases of s-PNET in adult patients. The follow-up analysis showed that these tumors have an aggressive clinical behavior. At the histopathologic level, they resembled their pediatric counterpart, showing a variable spectrum of neuronal differentiation. These cases did not show astrocytic differentiation; therefore, they did not qualify for the differential diagnosis of glioblastoma variants. The tumors were also screened for mutation of TP53, IDH1, IDH2, and b-catenin, using single strand conformation polymorphism-based and sequencing assays, and were analyzed for c-myc/N-myc gene copy numbers with a quantitative polymerase chain reaction-based method. The strand conformation polymorphism-based mutational analysis showed that 5 tumors harbored TP53 mutations. In 2 cases, a mutation at codon 132 of the IDH1 gene was also found. No mutations of the b-catenin or IDH2 genes were identified. No cases presented c-myc or N-myc amplifications. Only 1 case presented overexpression of epidermal growth factor receptor. In conclusion, our data show a high incidence of TP53 mutations in this group of tumors and show, in comparison with pediatric s-PNET, the absence of amplification of the c-myc/N-myc genes, indicating that s-PNET in adult patients may represent a specific subset of tumors among CNS-PNETs.
T he primitive neuroectodermal tumors of the central nervous system (CNS-PNET) are a heterogeneous group of neoplasms occurring in the CNS and are composed of undifferentiated or poorly differentiated neuroepithelial cells, which may show divergent differentiation along neuronal, astrocytic, and ependymal lines. 19 According to the revised World Health Organization (WHO) classification (2007), 19 this group includes the supratentorial primitive neuroectodermal tumors (s-PNET), affecting the cerebral hemispheres, which predominantly occur in childhood. 19 Despite multimodal therapy, less than half of the affected patients will survive 5 years postdiagnosis, and late effects associated with current treatment protocols are a significant complication in survivors. 5 Advances in the understanding of the molecular basis of s-PNET development will be critical to improve patient outcome. The biological mechanisms underlying s-PNET pathogenesis remain poorly understood and limited by their overall very low incidence. 19 In the past, various molecular pathways has been claimed to be implicated in s-PNET pathogenesis and biology, but, in contrast to medulloblastoma (MB), only few sporadic alterations of different pathway including RASSIF1A promoter methylation, 11 CDKN2A deletions, 25 p14 ARF methylation, 12 transcriptional silencing of DLC-1, 21 chr19q13.41 microRNA polycistron amplification, 18 and isocitrate dehydrogenase 1 (IDH1) mutations 1, 9 have been described.
Although many tumors occur in infancy and childhood, some cases may also arise in adult patients. These tumors share, "by definition," the same morphologic and immunhistochemical features of pediatric lesion but only few detailed histopathologic analyses of large case series are available. 2, 13 The morphology of s-PNET cells and the possible presence of glial differentiation in the tumor may simulate other more common malignant glial tumors in this age range (such as small cell glioblastoma and anaplastic oligodendroglioma). In addition, the description of glioblastoma cases with PNET-like components makes the definition and the diagnostic borders between s-PNET and glioblastoma more difficult. 24 Interestingly, the analysis of molecular data on adult s-PNET available suggests that they may have specific molecular features and potentially seem to be a well-defined subgroup among brain tumors. Moreover, they seem to have an increased overall survival in comparison with pediatric s-PNET. 13 To better define the spectrum of histopathologic features of s-PNET occurring in adult patients and to explore the possible presence of a common genetic background in these tumors, we analyzed the histopathologic features and the TP53, b-Catenin, N-myc, and c-myc and IDH1/IDH2 status in 12 cases of s-PNET in adults.
MATERIALS AND METHODS

Patients
Ten surgically obtained specimens (cases 1 to 4 and cases 8 to 12) were received for consultation at the German Brain Tumor Reference Center (Bonn, Germany) from 1998 to 2010. The other cases were contributed by the Department of Pathology, Catholic University, Rome, Italy (case 7; this case was already described as a single case report.) 30 and by the Department of Pathology IRCCS Casa Sollievo della Sofferenza, S. Giovanni Rotondo, Italy and Department of Experimental Medicine and Pathology, University of Rome "La Sapienza" (cases 5 to 6). All cases had been formalin fixed, routinely processed, and paraffin embedded. Five micron slide sections were stained with hematoxylin and eosin. Immunohistochemistry was performed on a TE-CAN semiautomated staining system using antibodies for vimentin (Dako, Glostrup, Denmark), MAP-2 (Dako), synaptophysin (Zymed, San Francisco), thyroid transcription factor-1 (TTF-1) (Zymed), glial fibrillary acidic protein (GFAP, Dako), neurofilament protein (Neomarkers, Freemont), BAF47/INI1 (BD Biosciences, Palo Alto), NeuN (Neomarkers) NSE (Dako), pancytokeratin (clone Lu-5, Bachem, Darmstadt, Germany), NCAM (Dako), and epithelial membrane antigen (Dako). Additional immunhistochemical stainings were performed using antibodies versus p53 (Dako), b-Catenin (BD Biosciences, Palo Alto), and epidermal growth factor receptor (EGFR) (Dako). The proliferation index was evaluated using the anti-Ki67 antibody (MIB-1, Dako). The diagnosis was confirmed by at least 3 different expert neuropathologists.
DNA Extraction
DNA from 11 formalin-fixed paraffin-embedded tissues was obtained using the QIAamp DNA Mini Tissue Kit (Qiagen GmbH, Du¨sseldorf, Germany) according to the manufacturer's instructions. Materials were selected for DNA extraction after careful examination of corresponding hematoxylin and eosin-stained sections. All samples selected contained at least 80% of vital tumor.
TP53 and b-Catenin Mutation Analysis
Exons 4 to 9 of the TP53 gene were screened for mutations by single strand conformation polymorphism (SSCP) analysis as reported earlier. 15 SSCP analysis was carried out using 10%, 12%, and 14% nondenaturing acrylamide gel electrophoresis at 5 to 10 W and variable temperatures for 12 to 18 hours. The gels were silver stained as described. 15 SSCP bands with aberrant migration were excised, reamplified with the same set of primers, and cloned into the TOPO TA cloning/pCR2.1 vector (Invitrogen, Karlsruhe, Germany). Inserts of individual bacterial clones were amplified using vectorspecific primers. Polymerase chain reaction (PCR) products were treated with ExoSAP-IT (USB, Staufen, Germany) following manufacturer's instructions and sequenced using the Big Dye Prism DNA cycle sequencing kit (Applied Biosystems, Darmstadt, Germany) on an Applied Biosystems 3130 Genetic Analyzer (Applied Biosystems). Five to ten individual clones were selected for each sample. The obtained sequences were compared with the TP53 mutation database (www.p53.iarc.fr). The PCR conditions and primer sequences for SSCP analysis of exon 3 of the b-Catenin gene have been described earlier. 14 
IDH 1 and IDH 2 Mutation Analysis
We screened codon 132 (exon 4) of the gene IDH1 and codon 172 (exon 4) of IDH2 for mutations using a pyrosequencing assay as reported in detail. 32 In brief, a 135 bp fragment of exon 4 of IDH1 containing the R132 coding region was amplified using the primers IDH1-fwd-5 0 -CACCATACGAAATATTCTGG-3 0 and IDH1-rev-5 0biotin-CAACATGACTTACTTGATCC-3 0 using 50 ng genomic DNA as template. Similarly, an 87 bp fragment of exon 4 of IDH2 containing the R172 coding region was amplified using the primer set IDH2-fwd-5 0 -AAA CATCCCACGCCTAGTCC-3 0 and IDH2-rev-5 0 -biotin-CTCCACCCTGGCCTACCT-3 0 . PCR-amplified products of IDH1 and IDH2 flanking the R132/R172 mutation hot spot within exon 4 were subjected to pyrosequencing reactions. For IDH1 R132, pyrosequencing primer IDH1-Py-5 0 -GTGAGTGGATGGATGGG TAAAACC-3 0 was used with the nucleotide dispensation order NGT-AGT/TGT/GGT (first base) CNT-CAT/ CTT/CCT (second base). IDH2 R172 was sequenced using the pyrosequencing primer IDH2-Py-5 0 -AGCC CATCACCATTG-3 0 with the nucleotide dispensation order NGG-GGT/CGT/TGT (first base), ANG-ACG/AAG/ATG (second base).
c-myc/N-myc Amplification Analysis
To quantify c-myc and N-myc gene copy numbers, exogenous DNA standard competitors were generated with internal deletions by in vitro mutagenesis as described earlier. 29, 35 Primer sequences, specific PCR conditions, and the fragment sizes were as follows: cmyc, 5 0 -TCTGGATCACCTTCTGCTGG-3 0 and 5 0 -AG GATAGTCCTTCCGAG TGG-3 0 , target 126 bp, standard 108 bp, and annealing temperature 581C; N-myc, 5 0 -TAAACGTTGGTGACGGAAGG-3 0 and 5 0 -TACA GAAATGTTCCCCAGGG-3 0 , target 167 bp, standard 150 bp, and annealing temperature 581C; and APRT (control gene), 5 0 -CAGGGAACACATTCCTTTGC-3 0 and 5 0 -TGGGAAAGCTGTTTACTGC-3 0 , target 135 bp, standard 121 bp, and annealing temperature 581C. To ensure coverage of the equimolar range of competitors and corresponding target DNAs, we performed titration experiments with serial dilutions of the competitors in a pool of tumor and normal tissue DNAs. Optimal titration was defined as the point of equal signal intensity of exogenous competitor and target. Subsequent PCR amplification of all products was carried out with a fluorescent-labeled reverse primer. Products were analyzed in 4.5% denaturating acrylamide gels on a DNA sequencing device (ABI 377) (Applied Biosystems) using the Genescan software (Applied Biosystems). Gene copy numbers were calculated as follows: [(TARGET sample/ TARGET standard)/(APRT sample/APRT standard)]. Gene amplification was defined as present if the ratio was higher than mean and 2-fold SD of the whole set of samples. Paraffin-embedded cerebellar tissue and paraffin-embedded MB tissue were used as negative and positive controls, respectively.
RESULTS
Clinical, Histopathologic, and Immunohistochemical Features
The patients presented a mean age of 53.5 years (range 32 to 64 y) at diagnosis. Six patients were women and 6 were men. From the clinical data available, no patients referred familiar cancer-predisposing syndromes or presence of other synchronous systemic tumors. The clinical data are summarized in Table 1 . All tumors included in our series affected the supratentorial region (s-PNET). No tumor arose in the cerebellar or pineal region. One patient presented multiple brain foci.
Data concerning follow-up (FU) and therapeutic management were available for 8 patients (mean FU: 1.5 y; range: 2 mo-5 y). With the exception of 1 case, the tumors presented a very aggressive clinical behavior with multiple local relapses and clinical tumor progression (Table 1) .
Neuroradiologic data were available for a subgroup of patients. The tumors appeared in most of the cases as well-delimitated lesions (Fig. 1 ) with a variable magnetic resonance imaging contrast enhancement, ranging from absent to diffuse. Calcifications were also present in a few cases. One case showed a cystic component.
According to WHO classification, 19 all cases qualified for the diagnosis of s-PNET or cerebral neuroblastoma (WHO grade IV) ( Table 2) .
All neoplasms were composed of undifferentiated cells with hyperchromatic cell nuclei and a scarce amount of cytoplasm ( Fig. 2A ). The mitotic activity was elevated. In 7 cases, scattered areas of nonpalisading necrosis were present. Vascular proliferations were also occasionally found. Neuronal differentiation, as neuropil areas or differentiated ganglion cells, was also focally encountered ( Fig. 2B ). Five cases showed Homer-Wright rosettes (Fig. 2C ).
Anaplastic features, characterized by increased cell and nuclear size with irregular, pleomorphic hyperchromatic nuclei, cell wrapping, necrosis, and atypical mitoses, were identified in 5 cases. Multinucleated bizarre giant cells characterized 2 cases with anaplastic features (Fig. 2D ). No tumors showed "large cell" features, similar to large cell MB. Three cases showed lobular architecture, sometimes with scattered fibrous intratumoral septa as well. Prominent nodularity and neuronal maturation with features partially resembling the histology of desmoplastic MB was only present in the ganglioneuroblastoma case ( Fig. 2E ). In 2 cases, a sharp demarcation between the tumor and the surrounding brain parenchyma was found. Calcifications, although focally observed in a few cases, were not a main feature in the cases that are reported here. None of the cases presented ependymoblastic differentiation or medulloepithelioma-like features.
All the cases studied presented a variable positivity for neuronal markers, including synaptophysin, NeuN, NF, NSE, and cytoplasmatic NCAM, and at least 1 of the neuronal markers used was positive. Eleven cases showed an intense cytoplasmatic positivity with MAP-2 antibody. A positive staining for synaptophysin was also identified in 5 cases (Fig. 2F ). NeuN staining was present in 3 cases. Positivity for vimentin was partially identified in 5 cases. Positive S100 staining was found in 5 cases; in 3 of them staining was present in only a limited subpopulation (<10%) of tumor cells. No cases showed tumor cell immunoreactivity for epithelial membrane antigen or pancytokeratin (Lu-5) and TTF-1. However, in only 1 tumor, isolated and rare GFAP-positive cells (<5% of all tumor cells), compatible with a minimal glial differentiation, have been found. The nuclear expression of BAF47/INI-1 was maintained. The mitotic activity and proliferative activity were elevated (MIB-1 ranging from 20% to 60%). The immunohistochemical analysis with antibody against the p53 showed that 8 cases presented a marked nuclear positivity (ranging from 20% to 80% of cells) ( Fig. 2G ). One case ( case 11) showed a strong cytoplasmic reactivity for EGFR. Case 9 was characterized by a nuclear accumulation of b-Catenin (Fig. 2H ).
TP53, b-Catenin, IDH1/IDH2 Mutation Analysis and c-myc/N-myc Amplification Analysis
The SSCP-based mutational screening of TP53 from exon 4 to exon 9 in 11 cases of adult s-PNET was carried out along with control DNA samples. Data are summarized in Table 1 . Case 1 showed a mutation at codon 273 (CGT-TGT, Arg-Cys) (exon 8). In case 2, a point mutation at codon 237 (ATG-ATT, Met-Ile) of exon 7 was found. Two cases (patients 8 and 4) had point mutations at codon 152 (CCG-CTG, Pro-Leu) and codon 175 (CGC-CAC, Arg-His) of exon 5, respectively ( Fig. 3) . In case 11, a point mutation at codon 125 (ACG-AGG, Thr-Arg) of exon 4 was identified (Fig. 3) . Moreover, 2 different DNA polymorphisms affecting exons 4 and 6 were also identified (not shown).
Using an SSCP-based method, we screened for the presence of point mutations affecting the b-Catenin exon 3 but the analysis did not show presence of shifts in SSCP acrylamide gels ( Table 1 ). The amplification product of case 9 showing a positive nuclear staining (Fig. 2H ) was cloned and sequenced. However, no point mutations were found.
We have also examined all cases for the presence of mutations of the IDH1 or IDH2 and for c-myc and N-myc amplification as well. In 2 cases (5 and 8) (Table 1) , a mutation in codon 132 of IDH1 gene was found ( Fig. 4) . No mutations of the IDH2 gene in codon 172 were identified ( Fig. 5 ). C-myc and N-myc DNA amplifications were not detected in any tumor samples.
DISCUSSION
Supratentorial PNETs (s-PNETs) are embryonal neoplasms of the CNS formed by small, undifferentiated cells affecting the cerebral hemispheres. They usually occur during childhood and seem to be very uncommon in adult life. 19 To date, only a few series of s-PNETs in adult patients have been reported and data on the molecular features of these rare tumors are limited. The patients included in our study showed a higher mean age (53.5 y) in comparison with the series of adult s-PNETs published. 2, 13 The tumors did not show a preferential site of localization. On computed tomographic or magnetic resonance images, the tumors appeared as well-delimitated, inhomogeneous, variably contrast-enhanced lesions. Tumor lobulation, intratumoral cysts, necrosis, hemorrhages, and calcifications were also observed in our cases and also in other cases reported. 13, 26 In terms of FU, the tumors showed a very aggressive clinical behavior despite radiotherapy or chemotherapy (Table  1) , in contrast to reports from other studies that showed an increased overall survival for this tumor type in adults, in comparison with those arising in the pediatric age. 13 S-PNETs in adults show a spectrum of histopathologic features similar to their pediatric counterpart. They ranged from cases showing extensive neuronal maturation with ganglioneuroblastoma-like features to cases with the presence of features of severe anaplasia. The prevalence of anaplastic features was similar to other published series in the literature. 2 We also identified 2 cases with abundant bizarre multinucleated giant cells, a feature rarely reported in CNS-PNET cases. 2, 19 As histopathologic features, the immunhistochemical profile of these tumors varied greatly as well. Except for MAP-2, present in >90% of cases, the expression of different neuronal markers (NeuN, synaptophysin, and NCAM) was quite variable and presented a consistent intratumoral and intertumoral variability, and correlated with the degree of neuronal maturation and presence of neuropil areas or ganglionlike cells. However, cases with anaplastic features showed intracytoplasmic positivity for synaptophysin, but without a dot-like pattern, as often observed in anaplastic/ large cell MB.
Malignant gliomas, such as small cell glioblastoma, could morphologically resemble s-PNET and may also secondarily develop clonal foci resembling PNET, morphologically and immunohistochemically. 24 Therefore, it is critical for the diagnosis of glioblastoma, the presence of a component that resembles diffuse glioma, and the presence of astroglial features in tumor cells. In our cases, we found no glial tumor component at the morphologic or immunohistochemical level. However, in only 1 case, isolated and rare GFAP-positive cells, compatible with a minimal glial differentiation, were found. In contrast, small cell glioblastomas usually show higher EGFR expression levels in comparison with other glioblastomas. 3, 23 We identified only a single case (<10% of cases in our series) with EGFR overexpression but it did not show immunoreactivity for GFAP. The possibility that a small focus of glioma was not sampled or that it was overshadowed by the PNET-like component cannot be fully excluded.
The p53 staining showed strong nuclear positivity (>20% of stained nuclei) in 9 cases, suggesting the presence of TP53 mutations. SSCP mutation screening of the TP53 gene showed point mutations of TP53 in 4 of these 9 cases. We comprehensively identified 5 mutations of TP53 in exons 4, 5, 7, and 8. The presence of TP53 mutations have been previously identified in CNS-PNET, mainly in adult patients. 10 However, TP53 mutations in PNET have also been occasionally reported in children, 4, 16, 27 but the overall incidence of somatic TP53 mutation in pediatric CNS-PNET seems to be very low. 16 In contrast, CNS-PNETs have been described in young patients with Li-Fraumeni syndrome. 28 With regard to the type of mutations identified in our series, only 2 mutations occurred in TP53 hot spot regions (codon 175 and codon 273). All the mutations have been described earlier and were present in the TP53 mutation database (www.p53.iarc.fr). Although a worse prognosis has been recently described in MB harboring TP53 mutations, 34 it seems that the dismal prognosis in adult s-PNETs is not related to the presence of TP53 mutations.
The potential role of TP53 in s-PNET genesis has also been confirmed in mouse models. Momota et al 20 showed that s-PNET-like tumors arise in p53 À / À mice after c-myc somatic cell gene transfer and the combination effect of b-Catenin activation promotes tumor progression and induces divergent differentiation. In contrast, p53 +/+ mice after c-Myc somatic cell gene transfer had a very low tumor incidence. These c-myc+ b-Catenin-induced CNS-PNETs were histologically similar to large cell/anaplastic MBs. 20 Although the presence of TP53 mutations seems to mainly occur in adult s-PNETs, nuclear accumulation of p53 has been described to be frequent not only in adults but also in pediatric CNS-PNETs. 7 This observation led to the hypothesis that the TP53 pathway is pivotal in CNS-PNET biology and can also be activated by mechanisms other than mutation.
The b-Catenin immunohistochemical analysis showed nuclear positivity in only 1 case, but no mutations or alterations affecting exon 3 of the b-Catenin gene were detected. However, the overall incidence of b-Catenin mutations in s-PNET seems to be very low. 14 The absence of point mutations in exon 3 does not exclude that the nuclear accumulation identified at the immunohistochemical level can be due to the presence of other types of alterations in this molecular pathway, that is large deletion of the b-Catenin genes or mutation of genes encoding other members of the WNT-b-Catenin pathway. 14 N-Myc and c-Myc gene amplifications have been reported in both MBs 8 and CNS-PNET. 2, 19 In MB, these alterations have been associated with aggressive clinical behavior and shortened patient survival, 31 and are common in the anaplastic/large cell variants. 6, 17, 33 In CNS-PNET, these alterations have been rarely assessed and amplifications have been described in approximately 50% of pediatric cases and seem to be uncommon in the few cases of adult s-PNETs studied. 2 In this view, we do not identify any amplification of c-myc and N-myc in our series.
In a recent study of malignant gliomas with PNETlike components, N-myc and c-myc gene amplifications were seen in 43% of cases within the PNET-like areas. 24 The absence of c-myc and N-myc amplifications in our wCase 2: a mutation at codon 237 (ATG-ATT, Met-Ile) (exon 7 of TP53). zCase 4: a mutation at codon 175 (CGC-CAC, Arg-His) (exon 5 of TP53). Case 8: a mutation in codon 152 (CCG-CTG, Pro-Leu) (exon 5 of TP53). Case 11: a mutation at codon 125 (ACG-AGG, Thr-Arg) (exon 4 of TP53) at beta-catenin exon 3. zTwo cases (5 and 8) presented a CGT-CAT at codon 132 of IDH1 gene (exon 4). #The tumor showed an intense and diffuse nuclear staining for b-Catenin; however, no mutations have been found. GNB indicates ganglioneuroblastoma; H-W, Homer-Wright rosettes; IHC, immunohistochemistry; NA, not available; WT, wild type.
cases further suggests that adult s-PNETs may be distinct from gliomas with PNET-like components. An intriguing finding is the presence of IDH1 mutations in s-PNET in 2 cases of our series (22%). Recent genome-wide mutational analysis of glioblastomas 22 showed somatic mutations of the gene IDH1 in a fraction of such tumors, most frequently in tumors that were known to have evolved from lower-grade gliomas (secondary glioblastomas). 36 IDH1 mutations that affected codon 132 of the IDH1 gene are present in >70% of WHO grade II and III astrocytomas and oligodendrogliomas and in secondary glioblastomas. Among embryonal tumors, no IDH1 or IDH2 mutations have been found in MB 1 or pediatric CNS-PNET. 1, 9 However, IDH1 mutations have been identified in adult s-PNETs. 1, 9 The significance of IDH1 mutations in this group of tumors and any functional contribution they may make to tumor development is, however, currently unclear. One patient of our series referred to a previous radiation treatment for a low-grade glial tumor; however, the IDH1 analysis did not show presence of mutation in this s-PNET case. Although glioblastoma harboring IDH1 mutations also had a very high frequency of TP53 mutations, 36 only 1 case of our series showed coexistence of both TP53 and IDH1 mutations.
In conclusion, the high incidence of TP53 mutations and the absence of amplification of the c-myc and N-myc genes indicate that s-PNET in adult patients may represent a specific subset of tumor among the CNS-PNETs. Moreover, further studies are needed to define the functional role of their molecular features (TP53 or IDH1 mutations) and the histologic features (ie, anaplastic features) in predicting the survival or the response to therapy in adult patients with s-PNET.
